<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02437422</url>
  </required_header>
  <id_info>
    <org_study_id>SGTP-001</org_study_id>
    <nct_id>NCT02437422</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease</brief_title>
  <official_title>A Phase Ib, Open-Label, Single Arm Study to Assess the Safety, Pharmacokinetics, and Impact on Humoral Sensitization of SANGUINATE Infusion in Patients With End-Stage Renal Disease (ESRD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prolong Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prolong Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase Ib, Open-Label, Single Arm Study to Assess the Safety, Pharmacokinetics, and Impact
      on Humoral Sensitization of SANGUINATE Infusion in Patients with End Stage Renal Disease
      (ESRD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to investigate the safety of SANGUINATE on humoral sensitization
      in End Stage Renal Disease (ESRD) patients receiving dialysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 5, 2015</start_date>
  <completion_date type="Actual">November 18, 2015</completion_date>
  <primary_completion_date type="Actual">November 18, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of study treatment as determined by changes in vital signs, electrocardiographic assessments, clinical signs, and bio-analytical measures (e.g., blood chemistry, hematology), and reported adverse events following infusion</measure>
    <time_frame>90 days</time_frame>
    <description>Composite endpoint with multiple vital signs, ECGs, clinical assessments and bio-analytical lab measurements over the 90 day time frame.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in the number of HLA-Antibody specificities determined by single antigen bead assays</measure>
    <time_frame>90 days</time_frame>
    <description>Antibody testing Human leukocyte antigen- antibody (HLA-Ab) HLA Tissue Typing (screening visit only) Calculated Panel Reactive Antibody (CPRA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in the overall strength of HLA-Antibody specificities determined by single antigen bead assays</measure>
    <time_frame>90 days</time_frame>
    <description>Antibody testing Human leukocyte antigen- antibody (HLA-Ab) HLA Tissue Typing (screening visit only) Calculated Panel Reactive Antibody (CPRA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in the calculated panel reactive antibody (CPRA)</measure>
    <time_frame>90 days</time_frame>
    <description>Antibody testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients with an increase in number of HLA-Ab specificities determined by single antigen bead assays</measure>
    <time_frame>90 Days</time_frame>
    <description>Antibody testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients with an increase in CPRA</measure>
    <time_frame>90 Days</time_frame>
    <description>Antibody testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile as determined from blood plasma over time (Tmax, Cmax, AUC, half-life, coefficient of variation, and the apparent elimination rate constant)</measure>
    <time_frame>22 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients with an increase in the overall strength of HLA-Antibodies</measure>
    <time_frame>90 Days</time_frame>
    <description>Antibody testing</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>SANGUINATE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single infusion of SANGUINATE</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SANGUINATE</intervention_name>
    <description>Single two-hour infusion of SANGUINATE</description>
    <arm_group_label>SANGUINATE</arm_group_label>
    <other_name>(pegylated carboxyhemoglobin bovine)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient diagnosed with End State Renal Disease requiring renal replacement therapy.

          2. Age 18 - 65 years of age who are on maintenance hemodialysis for at least 3 months
             prior to the study start;

          3. Stable dialysis treatment regimen 3 times per week for â‰¥ 2 months prior to screening
             visit;

          4. Hemoglobin &gt;7.5 g/dL with or without clinical symptoms;

          5. Women of childbearing potential must have a negative serum pregnancy test and must use
             a reliable method of contraception during the study period;

          6. Signed and dated informed written consent by the subject or his/her legally authorized
             representative;

        Exclusion Criteria:

          1. In the judgment of the investigator the patient is not a good candidate for the study;

          2. Blood transfusion with in the last 90 days from date of Screening;

          3. Symptoms or electrocardiogram (ECG)-based signs of acute myocardial infarction,
             Unstable angina pectoris, decompensated heart failure, third degree heart block or
             cardiac arrhythmia associated with hemodynamic instability;

          4. Total bilirubin greater than 1.5 mg/dL or transaminase (ALT, AST) elevations greater
             than 2 times the upper limit of the laboratory reference range or evidence of
             significant hepatic insufficiency;

          5. Concurrent or prior treatment within 90 days of Screening with an investigational
             medication;

          6. Chronic treatment (as determined by the Investigator) with any immunosuppressive
             medication (including corticosteroids) within the past 90 days of Screening;

          7. Evidence or history of regular alcohol abuse;

          8. Screening laboratory result(s) determined to be clinically significant by the
             investigator;

          9. Screening laboratory result indicating HIV-positivity, or previously diagnosed with
             AIDS, AIDS related complex or any other immunodeficiency;

         10. Screening laboratory result or laboratory results performed within one year indicating
             positivity for hepatitis B surface antigens, hepatitis B core antibodies, or hepatitis
             C antibodies;

         11. Uncontrolled Diabetes Mellitus (Patients with HbA1c &gt; 9% at screening)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bassam G Abu Jadweh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati/ Division of Nephrology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati/ Division of Nephrology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0585</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2015</study_first_submitted>
  <study_first_submitted_qc>May 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2015</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

